STOCK WATCH
■ OXFORD Biomedica will set up a manufacturing business with US group Homology Medicines. The FTSE 250 group will own 80pc of the firm.
But the company’s stock tumbled as it said it would fund the deal through a £64m loan, its current cash pot and a share sale in which it hopes to raise more than £80m.
It also announced a change of leadership. Chief executive John Dawson steps down, replaced by chairman Dr Roch Doliveux. Shares slid 10.2pc, or 92p, to 808p.
CITY & FINANCE
en-gb
2022-01-29T08:00:00.0000000Z
2022-01-29T08:00:00.0000000Z
https://mailonline.pressreader.com/article/282784949864265
dmg media (UK)